Imported shingles vaccine that has been suspended & delayed

Zostavax is out of stock at the end of June

The schedule for the introduction of the one-year permission Shingrix has been delayed. The possibility of introduction is low by the end of this year

The imported shingles vaccine is in short supply.

 

This is because MSD's Zostavax has been out of stock for a while and the introduction of Shingrix, which was approved last year, continues to be delayed.

 

According to the pharmaceutical industry on the 31st, Zostavax has been out of stock for about two months.

 

MSD, which announced the news of its out of stock at the end of June, said it would resume supply at the end of July, but it is expected that it will not be able to supply again until September due to the postponement of the schedule.

 

Zostavax was sold out in some regions due to a sudden increase in demand in 2020.

 

In this regard, an MSD official said, "Zostavax is experiencing a short-term out of stock, and we are trying to speed up the lot release screening process as much as possible." "If we complete the process quickly, we expect to resume supply in early September," he explained.

 

On top of that, GSK's new shingles vaccine Shingrix, which has been newly approved, has not been able to enter the domestic market for about a year due to continuous delay in its introduction schedule.

 

Shingrix, which was approved by the Ministry of Food and Drug Safety in September last year, was originally scheduled to be released in February this year, but it continued to be delayed to the middle and second half of this year due to the delay in the introduction schedule.

 

Shingrix was expected to rebound the size of the domestic shingles vaccine market.

 

Recently, sales in the shingles vaccine market have been falling.

 

According to IQVIA, a pharmaceutical market research firm, the size of the vaccine market for shingles prevention was KRW 45.1 billion last year, down 37.6% from KRW 72.3 billion a year earlier.

 

In the first half of this year, it was also worth 20.4 billion won, almost no difference from the previous year.

 

This is because many of the main target groups of shingles have been vaccinated, and in the case of shingles vaccines, they only need to be vaccinated once in their lives.

 

After 8 years, the immune effect decreases, so additional vaccinations are recommended, but the additional vaccination rate is relatively low.

 

The emergence of Shingrix is likely to increase the additional inoculation rate.

 

Shingrix gained attention by demonstrating stronger shingles prevention effects than Zostavax.

 

Clinical trials (ZOE-50) of adults aged 50 and older demonstrated a 97.2% ERA in 3.2 years of follow-up observation, and 3.7 years of follow-up observation (ZOE-70) showed 89.8% efficacy.

 

Compared to Zostavax's 5% ERA in patients over the age of 50 and 41% over the age of 70.

 

The industry predicts that Singrix will not be released this year at all.

 

GSK is in a position that "no decision has been made on the schedule for introducing Singrix," which is bolstered by this prospect.

 

GSK is also known to have decided on Singrix's domestic partner this year, but the release date is being delayed without any promise as the introduction in Korea is delayed.

 

Some say that Singrix's global demand is increasing and it is not able to secure supplies to enter the country.

 

This is because demand for Singrix, which had shrunk due to COVID-19, has risen significantly this year as it has been recovering since the second half of last year.

 

In the first half of last year, Singrix's sales more than doubled from the same period last year to 1.429 billion pounds (2.26 trillion won).

 

The industry this year, singgeuriksseu is looking to break sales a year.